Caris Life Sciences, Inc.
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
CAI$24.43-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| (amounts in thousands) | Three Months Ended March 31, | |
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(510) | $(102,581) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 5,065 | 7,045 |
| Stock-based compensation expense | 15,872 | 14,691 |
| Non-cash operating lease expense | 1,323 | 1,452 |
| Amortization of debt discounts | 2,624 | 1,945 |
| Changes in fair value of financial instruments | — | 32,333 |
| Other | 214 | 456 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 21,623 | 7,913 |
| Supplies | (13,328) | 2,061 |
| Prepaid expenses and other current assets | (1,554) | 2,470 |
| Other assets | 153 | 36 |
| Accounts payable | 16,371 | (1,739) |
| Accrued expenses and other liabilities | (14,977) | 2,580 |
| Net cash provided by (used in) operating activities | 32,876 | (31,338) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (10,342) | (2,689) |
| Net cash used in investing activities | (10,342) | (2,689) |
| Cash flows from financing activities | ||
| Payments made on finance lease obligations | (40) | (22) |
| Proceeds from exercise of stock options | 920 | 1,434 |
| Payment of taxes withheld from net settlement of exercised options and vested RSUs | (56) | — |
| Payment of deferred offering costs | — | (105) |
| Repurchase of common stock | — | (22) |
| Net cash provided by financing activities | 824 | 1,285 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (10) | 4 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 23,348 | (32,738) |
| Cash, cash equivalents, and restricted cash at beginning of period | 800,042 | 68,028 |
| Cash, cash equivalents, and restricted cash at end of period | $823,390 | $35,290 |
| Reconciliation of cash, cash equivalents, and restricted cash | ||
| Cash and cash equivalents | $819,901 | $31,201 |
| Restricted cash | 3,489 | 4,089 |
| Total cash, cash equivalents, and restricted cash | $823,390 | $35,290 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.